Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Rhythm Pharmaceuticals
ISIN US76243J1051
|WKN A2H5A0
Market cap (in EUR)
6,579 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 6,579 m |
| EPS, EUR | -2.71 |
| P/B ratio | 61.1 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 168 m |
| Net income, EUR | -174 m |
| Profit margin | -103.57% |
What ETF is Rhythm Pharmaceuticals in?
There are 33 ETFs which contain Rhythm Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Rhythm Pharmaceuticals is the Harbor Health Care UCITS ETF Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.